Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics.
about
X-ray Structures of Human Furin in Complex with Competitive InhibitorsDevelopment and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 proteaseNovel Furin Inhibitors with Potent Anti-infectious ActivityIdentification of a small molecule that selectively inhibits mouse PC2 over mouse PC1/3: a computational and experimental studyCleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitorsInhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2.Inhibitor screening of proprotein convertases using positional scanning libraries.Molecular Validation of PACE4 as a Target in Prostate CancerIdentification of potent and compartment-selective small molecule furin inhibitors using cell-based assays.Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth.Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives.Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.Endogenous secreted phospholipase A2 group X regulates cysteinyl leukotrienes synthesis by human eosinophils.Generation and characterization of non-competitive furin-inhibiting nanobodies.Purification of the proprotein convertase furin by affinity chromatography based on PC-specific inhibitors.On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.Targeting bacterial toxins.The chemistry and biology of organic guanidine derivatives.Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium.Antiviral strategies against influenza virus: towards new therapeutic approaches.Therapeutic uses of furin and its inhibitors: a patent review.Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure.PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.Elongated and Shortened Peptidomimetic Inhibitors of the Proprotein Convertase Furin.New furin inhibitors based on weakly basic amidinohydrazones.Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus.Chemical structure and properties of low-molecular furin inhibitors.Optimization of Substrate-Analogue Furin Inhibitors.Engineering a Constrained Peptidic Scaffold towards Potent and Selective Furin Inhibitors.Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.[Strategies for development of new influenza medication].
P2860
Q27682457-F4D6BE8E-9A97-43B7-B48F-BF35D7105A94Q27683750-0C1B61C4-079F-4994-A4DD-A74873E130C3Q27700845-F5F65411-C89A-4E43-B798-911FDAB16659Q28486655-7EB7D0D7-D108-4357-A0BA-7E92C99F59EBQ30386796-C31380E1-F797-4D1B-88BA-1E7A2CFBF7A0Q30396910-2ABC9DC4-EE12-4D6F-9DB5-B86290A9E7FDQ33976691-10AB3578-AC43-4BD4-8F37-DEA11152078DQ35015483-4ADD928C-AF82-42B3-A52F-E1384CE39002Q35744263-AF2F3E98-8657-4707-B3B3-5DB8772BA3D9Q35763764-B2EB1884-72E6-4313-8787-26DB4F5F2B73Q35776764-5F239BA4-A529-4859-899D-FA9FC7A3AB14Q36052463-81305F39-7686-4098-8C5F-7E1CEC501D11Q36414954-465A9C82-CD18-4862-A1C1-4E36A1A5DB74Q36533737-4B85273F-F805-4DA1-8C0C-476AEC8B8672Q37217236-12E5898E-BB28-45F5-BE10-BF4FED4A4BA8Q37981645-F9AE37ED-3862-40C8-B3F2-9D90BA84EEA9Q37996325-146B251B-8A70-41E2-BE1F-60D7158D1A21Q38044691-578F69EC-D4A6-4D9A-823E-1149551A274EQ38118946-AB1DF050-4F35-40ED-A4E6-9160EDDE37CAQ38202012-D2F9898F-6464-49DA-8A3D-2E2665706902Q38309128-24BF04A0-94E2-46E1-A89A-5645D9B407FCQ38424871-B0A014A5-46E3-4302-B9DB-694B81CE8B3EQ38909525-0F4847B9-3482-4575-B58A-4EF3ED01FAA8Q39175999-1116E25B-29B9-4F1D-A61E-5879D4FE1613Q40277816-FA82AC19-E843-4404-9D89-A91AC7F14275Q41956540-D034BB70-0526-49B1-805D-56F8E5643365Q45258803-ED6F2584-D824-4B46-8434-DD6A5E3F88DEQ47318814-97416D5D-C5E3-4122-8CB7-7BB128B6BF08Q47420797-51926BC5-EA94-4E12-A462-520B37D06D42Q51700733-B0C67020-DBAA-47A4-B4C7-E16162DD0059Q53099256-7642E6FF-78C1-4748-90F7-3373EF5726A3Q54586007-988DC488-01AD-4518-B1D5-1ED98FA5350D
P2860
Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@en
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@nl
type
label
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@en
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@nl
prefLabel
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@en
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@nl
P2093
P2860
P356
P1476
Potent inhibitors of furin and ...... oxylated P1 arginine mimetics.
@en
P2093
Frank Sielaff
Gero L Becker
Iris Lindberg
Manuel E Than
Robert Day
Sophie Routhier
Torsten Steinmetzer
Wolfgang Garten
Yinghui Lu
P2860
P304
P356
10.1021/JM9012455
P407
P577
2010-02-01T00:00:00Z